STOCKS TELEGRAPH

Tag: Phio Pharmaceuticals

  • Market Responds Positively To Phio Pharmaceuticals’ Strategic Direction

    Market Responds Positively To Phio Pharmaceuticals’ Strategic Direction

    The clinical-stage biopharmaceutical company Phio Pharmaceuticals Corp. (NASDAQ: PHIO), which specializes in siRNA-based cancer treatments, saw a sharp rise in stock value after launching a new strategic strategy. As of the latest transaction data, PHIO shares were up 7.42% to $3.18, reflecting investor confidence in the company’s growing emphasis.

    Increasing the Therapeutic Potential of INTASYL

    The business is developing its in-house INTASYL gene silencing technology, which consists of a pipeline of about 30 chemicals at the moment. With its recently revealed strategic plan, Phio hopes to raise awareness of the portfolio’s wider applications.

    This action comes after the current Phase 1b dosage escalation study of PH-762, an INTASYL chemical used to treat skin cancer, showed encouraging interim safety and effectiveness results. Preclinical and clinical evidence suggest that INTASYL may find application in a broader number of therapeutic domains.

    Change in Leadership to Promote Development

    Phio announced significant leadership changes that would take effect on June 9, 2025, in support of these goals. Former Chief Financial Officer Mr. Robert Infarinato has been promoted to Vice President of Strategic Development. Mr. Infarinato will spearhead business development initiatives aimed at extending the INTASYL platform’s strategic reach in his new position.

    With more than thirty years of expertise in operations and finance, Mr. Infarinato has held high-level roles such as Chairman of the Board of Trustees of Abington Health and Executive Vice President and CFO of a global services organization.

    Strengthened Finance Leadership

    Ms. Lisa Carson was appointed Vice President of Finance and Administration at the same time. With more than 20 years of experience in finance leadership, Carson joined Phio in May 2025.

    She previously served as Controller and Vice President of Finance at Prelude Therapeutics being  a key player in the IPO and growth of the business over time. Moreover, her previous roles at TELA Bio and PhaseBio Pharmaceuticals attest to her expertise in biopharma finance operations.

    These key hires demonstrate Phio’s dedication to developing its cutting-edge siRNA technology and increasing shareholder value via focused research and strengthened leadership.

  • Pre-Market Surge For Phio Pharmaceuticals Following Clinical Success

    Pre-Market Surge For Phio Pharmaceuticals Following Clinical Success

    Shares of Phio Pharmaceuticals Corp. (NASDAQ: PHIO) have been sharply rising on the charts following the release of encouraging clinical trial results. Its stock price has grown an astounding 130.18% to $3.89 per share as of the most recent pre-market check.

    PHIO Shared Clinical Studies Showing Favorable Results

    Phio Pharmaceuticals, a clinical-stage biotechnology business, is expanding its range of medications by employing its proprietary INTASYL siRNA gene silencing technology. This strategy aims to improve immune cells’ ability to identify and eliminate cancer cells.

    Today, patients in the second cohort of the current Phase 1b clinical research by Phio Pharmaceuticals showed encouraging pathologic responses. Two patients had a full response, indicating 100% tumor removal, according to the data. 

    Phase 1b Study Progress and Tumor Response Results

    The purpose of the Phase 1b clinical research (NCT 06014086) is to assess the safety and tolerability of administering PH-762 intratumorally to patients who have metastatic melanoma, Merkel cell carcinoma, or advanced types of cutaneous squamous cell carcinoma. Of the patients enrolled, six were diagnosed with cutaneous squamous cell carcinoma, and one with metastatic melanoma.

    The latest data from the second cohort, which includes four patients, demonstrated significant tumor responses. Two patients with cutaneous squamous cell carcinoma achieved complete tumor clearance, while a third reported a partial response with 90% tumor reduction.

    Reassuring Safety Data and Future Outlook

    In addition to the encouraging therapeutic responses, the trial has reported no dose-limiting toxicities or clinically significant adverse events. The intratumoral PH-762 injections have been well tolerated, further bolstering the safety profile of the treatment.

    Phio Pharmaceuticals is hopeful that more people will sign up for the experiment so that larger dosage concentrations of PH-762 may be tested. The company’s future is bright thanks to these encouraging early dosage escalation findings, as Phio Pharmaceuticals keeps up its revolutionary application of INTASYL technology in pursuit of a cancer-free future.

  • Phio Pharmaceuticals Rallies Following Key Trial and Funding Updates

    Phio Pharmaceuticals Rallies Following Key Trial and Funding Updates

    As of the last check during the recent trading session, Phio Pharmaceuticals Corp. (NASDAQ: PHIO) shares were up 33.81% to $2.36, indicating a big increase in value today. The spike in PHIO stock is due to a recently announced equity offering and positive outcomes from clinical research.

    Inspiration Findings from the PH-762 Clinical Trial

    According to Phio Pharmaceuticals, dosage escalation in the ongoing Phase 1b clinical investigation for PH-762 has been approved by the Safety Monitoring Committee or SMC. The safety and tolerability of this new intratumoral injection treatment are being investigated in patients with advanced Merkel cell carcinoma, melanoma, and cutaneous squamous cell carcinoma.

    Treatment for cutaneous squamous cell carcinoma was administered to the second set of study participants. Two patients who finished treatment showed a partial response with 90% tumor clearance, while one patient had a full response with 100% tumor elimination.

    Plans for Funding and Equity Offering 

    Final agreements for the sale of 437,192 common shares in a registered direct offering at a price of $2.635 per share were signed, according to a separate announcement from Phio Pharmaceuticals. Concurrently, the company will issue unregistered warrants that allow for the purchase of an equivalent number of shares at an exercise price of $2.51 per share. These warrants have a five-year expiry date and an immediate exercise period.

    The offering is expected to generate about $1.15 million in gross sales before expenses when it closes on December 20, 2024. PHIO is in plans to use the net proceeds for operating capital and general corporate purposes.

    The Positive Trends of Phio Pharmaceuticals 

    Phio Pharmaceuticals is setting itself up for expansion with encouraging clinical findings and calculated financial decisions. The latest advancements demonstrate not just PH-762’s promise as a ground-breaking cancer treatment, but also the company’s dedication to developing its pipeline and obtaining the required capital.